We have received the following statement from Mallinckrodt Pharmaceuticals, stating their intention to discontinue clinical development of adrabetadex (VTS-270) for Niemann-Pick Type C1 disease (NPC), effective immediately. We understand that this will be very difficult news for many within our community; the NPUK team will be available if you would like to contact us: email info@npuk.org or telephone 0191 415 06 93.
MNK Announcement Jan 2021 NPUKA community webinar will take place on Friday 22nd January at 17.30. The webinar will feature Dr. Steve Romano, Executive Vice President and Chief Scientific Officer at Mallinckrodt, and Dr. Susan VanMeter, Senior Clinical Director, who will address this latest news and take your questions. Please find details below:
Date: Friday, January 22
Time: 17.30- 18.30 GMT 12:30-1:30 p.m. EST
Join Zoom Meeting:
https://notredame.zoom.us/j/93703585673?pwd=emxnRmxTb2NaZjFNQ2tySGN6elFMUT09
Passcode: 050409
